Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
United Immunity Co., Ltd., Tokyo, Japan.
J Control Release. 2022 Jul;347:175-182. doi: 10.1016/j.jconrel.2022.05.004. Epub 2022 May 11.
In therapeutic cancer vaccines, vaccine antigens must be efficiently delivered to the antigen-presenting cells (dendritic cells and macrophages) located in the lymphoid organs (lymph nodes and spleen) at the appropriate time to induce a potent antitumor immune response. Nanoparticle-based delivery systems in cancer immunotherapy are of great interest in recent year. We have developed a novel cancer vaccine that can use self-assembled polysaccharide nanogel of cholesteryl group-modified pullulan (CHP) as an antigen delivery system for clinical cancer immunotherapy for the first time. Additionally, we recently proposed a novel technology that uses CHP nanogels to regulate the function of tumor-associated macrophages, leading to an improvement in the tumor microenvironment. When combined with other immunotherapies, macrophage function modulation using CHP nanogels demonstrated a potent inhibitory effect against cancers resistant to immune checkpoint inhibition therapies. In this review, we discuss the applications of our unique drug nanodelivery system for CHP nanogels.
在治疗性癌症疫苗中，疫苗抗原必须在适当的时间有效地递送到位于淋巴器官（淋巴结和脾脏）中的抗原呈递细胞（树突状细胞和巨噬细胞），以诱导有效的抗肿瘤免疫反应。近年来，基于纳米粒子的递药系统在癌症免疫治疗中受到了极大关注。我们首次开发了一种新型癌症疫苗，该疫苗可以将胆固醇基修饰普鲁兰的自组装多糖纳米凝胶（CHP）用作临床癌症免疫治疗的抗原递药系统。此外，我们最近提出了一种新的技术，该技术使用 CHP 纳米凝胶来调节肿瘤相关巨噬细胞的功能，从而改善肿瘤微环境。当与其他免疫疗法联合使用时，使用 CHP 纳米凝胶调节巨噬细胞功能对抵抗免疫检查点抑制疗法的癌症具有很强的抑制作用。在这篇综述中，我们讨论了我们独特的药物递药系统 CHP 纳米凝胶的应用。
